Parents of young kids were seemingly dealt another blow when the FDA delayed authorization of Pfizer's twoshot dose of the vaccine for children younger than 5 years old. While disappointing, it's not all bad news. To start, the surgeon general pointed out in an interview on Scary Mommy’s Live Work Thrive that the reason behind the FDA’s delay is to analyze additional data on the effectiveness of a third shot.

Murthy emphasized how this is a good example of the FDA being proactive. “If there was any chance two doses could give good protection to our children, they wanted to know that,” he says. “They concluded after looking that they had to wait for the data from three doses.” While unable to provide an exact timetable, Murthy estimated that it may take until April to get the data from that trial and said no corners will be cut in the process.